Neopharmed Gentili says companies now approach it after BioCryst Europe deal, at Jefferies London
Neopharmed Gentili's Matteo Meazzini told the Jefferies Global Healthcare Conference in London that the Italian company's European rare disease business, built on BioCryst's ORLADEYO operations, now draws approaches from other companies, and that it plans to keep adding products.
